Switch to:
Also traded in: Canada, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt N/A
VRX's Cash to Debt is ranked higher than
83% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.46 vs. VRX: N/A )
Ranked among companies with meaningful Cash to Debt only.
VRX' s Cash to Debt Range Over the Past 10 Years
Min: -1.06  Med: 0.24 Max: No Debt
Current: N/A
-1.06
No Debt
Equity to Asset 0.13
VRX's Equity to Asset is ranked lower than
96% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. VRX: 0.13 )
Ranked among companies with meaningful Equity to Asset only.
VRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.13  Med: 0.52 Max: 0.85
Current: 0.13
0.13
0.85
Interest Coverage 1.00
VRX's Interest Coverage is ranked lower than
94% of the 458 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.68 vs. VRX: 1.00 )
Ranked among companies with meaningful Interest Coverage only.
VRX' s Interest Coverage Range Over the Past 10 Years
Min: 0.17  Med: 7.04 Max: 121.91
Current: 1
0.17
121.91
F-Score: 7
Z-Score: 0.48
M-Score: -2.12
WACC vs ROIC
5.58%
-11.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 14.68
VRX's Operating margin (%) is ranked higher than
70% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. VRX: 14.68 )
Ranked among companies with meaningful Operating margin (%) only.
VRX' s Operating margin (%) Range Over the Past 10 Years
Min: -9.32  Med: 19.24 Max: 33.39
Current: 14.68
-9.32
33.39
Net-margin (%) -2.69
VRX's Net-margin (%) is ranked lower than
77% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. VRX: -2.69 )
Ranked among companies with meaningful Net-margin (%) only.
VRX' s Net-margin (%) Range Over the Past 10 Years
Min: -17.62  Med: 15.44 Max: 26.4
Current: -2.69
-17.62
26.4
ROE (%) -5.07
VRX's ROE (%) is ranked lower than
75% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. VRX: -5.07 )
Ranked among companies with meaningful ROE (%) only.
VRX' s ROE (%) Range Over the Past 10 Years
Min: -20.19  Med: 13.39 Max: 21.19
Current: -5.07
-20.19
21.19
ROA (%) -0.79
VRX's ROA (%) is ranked lower than
71% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.85 vs. VRX: -0.79 )
Ranked among companies with meaningful ROA (%) only.
VRX' s ROA (%) Range Over the Past 10 Years
Min: -3.88  Med: 6.21 Max: 13.02
Current: -0.79
-3.88
13.02
ROC (Joel Greenblatt) (%) 31.71
VRX's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.64 vs. VRX: 31.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -69.93  Med: 82.71 Max: 144.06
Current: 31.71
-69.93
144.06
Revenue Growth (3Y)(%) 54.10
VRX's Revenue Growth (3Y)(%) is ranked higher than
95% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.10 vs. VRX: 54.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.8  Med: 15.25 Max: 55.3
Current: 54.1
-10.8
55.3
EBITDA Growth (3Y)(%) 63.90
VRX's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. VRX: 63.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
VRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.7  Med: 15.60 Max: 113.3
Current: 63.9
-35.7
113.3
EPS Growth (3Y)(%) 83.30
VRX's EPS Growth (3Y)(%) is ranked higher than
95% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. VRX: 83.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
VRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.1  Med: 5.75 Max: 83.3
Current: 83.3
-37.1
83.3
» VRX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

VRX Guru Trades in Q1 2015

Bill Ackman 19,473,933 sh (New)
Jim Simons 475,837 sh (+1120.44%)
John Paulson 2,050,000 sh (+293.70%)
Louis Moore Bacon 30,063 sh (+110.44%)
Jeremy Grantham 1,155,927 sh (+10.91%)
Lou Simpson 1,898,540 sh (+5.81%)
Diamond Hill Capital 179,505 sh (+4.66%)
Private Capital 295,320 sh (+0.86%)
First Eagle Investment 1,191,832 sh (unchged)
Jeff Ubben 19,383,877 sh (unchged)
Steven Cohen Sold Out
George Soros Sold Out
Ruane Cunniff 34,089,378 sh (-0.71%)
Glenn Greenberg 5,877,016 sh (-4.07%)
Steve Mandel 5,569,460 sh (-32.50%)
Wallace Weitz 917,261 sh (-33.46%)
Chris Davis 1,877,040 sh (-46.50%)
Lee Ainslie 1,275,861 sh (-47.36%)
Andreas Halvorsen 4,058,343 sh (-55.29%)
Jana Partners 1,571,454 sh (-63.52%)
Joel Greenblatt 65,531 sh (-77.83%)
Paul Tudor Jones 1,256 sh (-98.74%)
» More
Q2 2015

VRX Guru Trades in Q2 2015

George Soros 9,254 sh (New)
Steven Cohen 42,900 sh (New)
Ken Fisher 1,828 sh (New)
Kyle Bass 10,198 sh (New)
John Paulson 9,000,000 sh (+339.02%)
Jeremy Grantham 1,708,746 sh (+47.82%)
Andreas Halvorsen 4,616,738 sh (+13.76%)
Private Capital 302,715 sh (+2.50%)
Glenn Greenberg 2,500 sh (unchged)
Bill Ackman 19,473,933 sh (unchged)
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
Ruane Cunniff 33,884,050 sh (-0.60%)
Glenn Greenberg 5,701,010 sh (-2.99%)
Steve Mandel 5,310,143 sh (-4.66%)
Chris Davis 1,762,238 sh (-6.12%)
Joel Greenblatt 61,178 sh (-6.64%)
Lou Simpson 1,728,265 sh (-8.97%)
First Eagle Investment 1,055,332 sh (-11.45%)
Jana Partners 1,342,723 sh (-14.56%)
Wallace Weitz 716,730 sh (-21.86%)
Jeff Ubben 14,994,261 sh (-22.65%)
Diamond Hill Capital 130,617 sh (-27.23%)
Lee Ainslie 756,609 sh (-40.70%)
Jim Simons 107,789 sh (-77.35%)
» More
Q3 2015

VRX Guru Trades in Q3 2015

Leon Cooperman 484,915 sh (New)
Jeremy Grantham 8,176,586 sh (+378.51%)
Joel Greenblatt 88,677 sh (+44.95%)
Steve Mandel 7,461,780 sh (+40.52%)
Diamond Hill Capital 169,542 sh (+29.80%)
Lou Simpson 1,952,983 sh (+13.00%)
Andreas Halvorsen 4,993,353 sh (+8.16%)
Lee Ainslie 811,361 sh (+7.24%)
Ken Fisher 1,833 sh (+0.27%)
Ruane Cunniff 33,922,192 sh (+0.11%)
First Eagle Investment 1,055 sh (unchged)
First Eagle Investment 1,055,332 sh (unchged)
Bill Ackman 19,473,933 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
Jim Simons Sold Out
Kyle Bass Sold Out
Jana Partners Sold Out
George Soros Sold Out
Steven Cohen Sold Out
John Paulson 8,890,000 sh (-1.22%)
Private Capital 296,931 sh (-1.91%)
Glenn Greenberg 5,577,892 sh (-2.16%)
Wallace Weitz 630,155 sh (-12.08%)
Chris Davis 1,509,122 sh (-14.36%)
» More
Q4 2015

VRX Guru Trades in Q4 2015

Steven Cohen 17,900 sh (New)
Jana Partners 1,565,935 sh (New)
Chris Davis 3,784,012 sh (+150.74%)
Diamond Hill Capital 301,374 sh (+77.76%)
Andreas Halvorsen 7,793,397 sh (+56.08%)
First Eagle Investment 1,640,132 sh (+55.41%)
John Paulson 13,265,900 sh (+49.22%)
Lou Simpson 2,698,614 sh (+38.18%)
Private Capital 336,306 sh (+13.26%)
Glenn Greenberg 6,252,331 sh (+12.09%)
Ruane Cunniff 35,375,610 sh (+4.28%)
First Eagle Investment 2,500 sh (unchged)
First Eagle Investment 2,000 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
Ken Fisher Sold Out
Leon Cooperman Sold Out
Wallace Weitz Sold Out
Lee Ainslie Sold Out
Joel Greenblatt Sold Out
Bill Ackman 16,591,122 sh (-14.80%)
Steve Mandel 5,829,079 sh (-21.88%)
Jeremy Grantham 4,393,848 sh (-46.26%)
» More
» Details

Insider Trades

Latest Guru Trades with VRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 2.81
VRX's Forward P/E is ranked higher than
97% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.85 vs. VRX: 2.81 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 7.48
VRX's Price/Owner Earnings (ttm) is ranked higher than
91% of the 261 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.99 vs. VRX: 7.48 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
VRX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.64  Med: 21.37 Max: 411.19
Current: 7.48
4.64
411.19
P/B 1.74
VRX's P/B is ranked higher than
69% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.94 vs. VRX: 1.74 )
Ranked among companies with meaningful P/B only.
VRX' s P/B Range Over the Past 10 Years
Min: 1.03  Med: 3.00 Max: 14.44
Current: 1.74
1.03
14.44
P/S 1.21
VRX's P/S is ranked higher than
76% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.78 vs. VRX: 1.21 )
Ranked among companies with meaningful P/S only.
VRX' s P/S Range Over the Past 10 Years
Min: 0.97  Med: 4.01 Max: 10.42
Current: 1.21
0.97
10.42
PFCF 5.65
VRX's PFCF is ranked higher than
91% of the 194 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.93 vs. VRX: 5.65 )
Ranked among companies with meaningful PFCF only.
VRX' s PFCF Range Over the Past 10 Years
Min: 2.67  Med: 14.68 Max: 450.3
Current: 5.65
2.67
450.3
POCF 4.78
VRX's POCF is ranked higher than
89% of the 253 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.08 vs. VRX: 4.78 )
Ranked among companies with meaningful POCF only.
VRX' s POCF Range Over the Past 10 Years
Min: 3.96  Med: 10.95 Max: 47.76
Current: 4.78
3.96
47.76
EV-to-EBIT 21.57
VRX's EV-to-EBIT is ranked lower than
56% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.82 vs. VRX: 21.57 )
Ranked among companies with meaningful EV-to-EBIT only.
VRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -1217.7  Med: 12.60 Max: 379.7
Current: 21.57
-1217.7
379.7
EV-to-EBITDA 10.05
VRX's EV-to-EBITDA is ranked higher than
74% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.62 vs. VRX: 10.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
VRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31  Med: 14.60 Max: 106.7
Current: 10.05
-31
106.7
PEG 0.40
VRX's PEG is ranked higher than
93% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.88 vs. VRX: 0.40 )
Ranked among companies with meaningful PEG only.
VRX' s PEG Range Over the Past 10 Years
Min: 0.21  Med: 2.22 Max: 249.36
Current: 0.4
0.21
249.36
Shiller P/E 61.37
VRX's Shiller P/E is ranked lower than
66% of the 140 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.65 vs. VRX: 61.37 )
Ranked among companies with meaningful Shiller P/E only.
VRX' s Shiller P/E Range Over the Past 10 Years
Min: 8.8  Med: 42.58 Max: 462.51
Current: 61.37
8.8
462.51
Current Ratio 1.50
VRX's Current Ratio is ranked lower than
71% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. VRX: 1.50 )
Ranked among companies with meaningful Current Ratio only.
VRX' s Current Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.63 Max: 9.68
Current: 1.5
0.72
9.68
Quick Ratio 1.25
VRX's Quick Ratio is ranked lower than
66% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. VRX: 1.25 )
Ranked among companies with meaningful Quick Ratio only.
VRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.25 Max: 9.3
Current: 1.25
0.59
9.3
Days Inventory 137.71
VRX's Days Inventory is ranked lower than
62% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.44 vs. VRX: 137.71 )
Ranked among companies with meaningful Days Inventory only.
VRX' s Days Inventory Range Over the Past 10 Years
Min: 115.82  Med: 142.55 Max: 185.86
Current: 137.71
115.82
185.86
Days Sales Outstanding 95.54
VRX's Days Sales Outstanding is ranked lower than
65% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.18 vs. VRX: 95.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.41  Med: 61.04 Max: 106.05
Current: 95.54
43.41
106.05
Days Payable 67.06
VRX's Days Payable is ranked lower than
53% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.90 vs. VRX: 67.06 )
Ranked among companies with meaningful Days Payable only.
VRX' s Days Payable Range Over the Past 10 Years
Min: 62.65  Med: 82.46 Max: 120.5
Current: 67.06
62.65
120.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.66
VRX's Price/Projected FCF is ranked higher than
94% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.83 vs. VRX: 0.66 )
Ranked among companies with meaningful Price/Projected FCF only.
VRX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.33  Med: 2.02 Max: 11.22
Current: 0.66
0.33
11.22
Price/Median PS Value 0.29
VRX's Price/Median PS Value is ranked higher than
96% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. VRX: 0.29 )
Ranked among companies with meaningful Price/Median PS Value only.
VRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 1.57 Max: 5.12
Current: 0.29
0.5
5.12
Price/Peter Lynch Fair Value 0.82
VRX's Price/Peter Lynch Fair Value is ranked higher than
82% of the 174 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.59 vs. VRX: 0.82 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
VRX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.67  Med: 2.61 Max: 104.35
Current: 0.82
0.67
104.35
Earnings Yield (Greenblatt) (%) 4.56
VRX's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. VRX: 4.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 5.05 Max: 22.8
Current: 4.56
0.3
22.8
Forward Rate of Return (Yacktman) (%) 86.51
VRX's Forward Rate of Return (Yacktman) (%) is ranked higher than
98% of the 315 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. VRX: 86.51 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
VRX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 2.5  Med: 16.70 Max: 91.7
Current: 86.51
2.5
91.7

More Statistics

Revenue(Mil) $10499
EPS $ -0.78
Beta0.15
Short Percentage of Float6.38%
52-Week Range $25.27 - 263.81
Shares Outstanding(Mil)343.10

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 14,051 15,325 16,534
EPS($) 11.45 14.91 15.27
EPS without NRI($) 11.45 14.91 15.27

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, NYSE:TEVA, TSE:4502, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:VRX.Canada, BVF.Germany, VRX N.Mexico, VRX.Switzerland, 0QYW.UK,
Valeant Pharmaceuticals International Inc was formed under the Business Corporations Act (Ontario) on February 18, 2000, as a result of the amalgamation of TXM Corporation and Biovail Corporation International. Biovail was continued under the Canada Business Corporations Act effective June 29, 2005. In connection with the acquisition of Valeant Pharmaceuticals International (Valeant) in September 2010, Biovail was renamed Valeant Pharmaceuticals International, Inc. It is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter products OTC, and medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices, which are marketed directly or indirectly in over 100 countries. The Company operates in two segments; Developed Markets and Emerging Markets. In the Developed Markets segment, it focuses its efforts in the eye health, dermatology, and neurology therapeutic classes. The Developed Markets segment consists of four reporting units based on geography, namely; U.S., Canada and Australia, Western Europe, and Japan. In the Emerging Markets segment, it focuses on branded generics, OTC products, and medical devices. The Emerging Markets segment consists of three reporting units based on geography, namely; Central & Eastern Europe, Middle East and North Africa, Latin America, and Asia & South Africa. Its principal pharmaceutical products are; Wellbutrin XL, Xenazine, Zovirax Cream, Zovirax, Lotemax, Arestin and Prolensa. Its principal OTC products are; PreserVision, ReNu Multiplus, Ocuvite, Artelac, and CeraVe. The Company relies on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of its technology and business. Its top four geographic markets are; the U.S. and Puerto Rico, Canada, Poland and Russia. The Company competes with specialty and other pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, the EU and in other countries in which it market its products. The principal raw materials, including active pharmaceutical ingredient, used by the Company "or its third party manufacturers" for its various products are purchased in the open market or are otherwise available from several sources. The Company is subject to extensive U.S. federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulation in Canada and similar regulations in foreign countries in which it may conduct its business.
» More Articles for NYSE:VRX

Headlines

Articles On GuruFocus.com
Ackman to Testify About Valeant Before Senate Apr 26 2016 
Weitz Funds' Research Fund Commentary 1st Quarter Apr 25 2016 
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
Wallace Weitz Comments on Valeant Pharmaceuticals Apr 22 2016 
Bernard Horn's 1st Quarter 2016 Polaris Global Value Fund Apr 22 2016 
Weitz Value Funds' 1st Quarter 2016 Commentry Apr 22 2016 
With Ackman Down It May Be Right Time to Back Him Apr 21 2016 
Mawer's Investment Newsletter 1st Quarter Apr 15 2016 
2 Major Mergers Come to End After Tough Stance From Regulators Apr 07 2016 
Notes From the Pershing Square 1st Quarter Call Apr 07 2016 

More From Other Websites
[$$] Valeant’s 10-K Lands: Another Step Away From the Edge Apr 29 2016
[$$] Valeant Files Overdue Annual Report, Shakes Up Its Board Apr 29 2016
Ackman to Buffett, Munger: Can't We Get Along Apr 29 2016
U.S. Stocks Sputter to April's End Apr 29 2016
Business Highlights Apr 29 2016
Valeant's Overdue SEC Filing Answers Some Big Questions, But Raises New Concerns Apr 29 2016
Worst may be over for embattled pharma Apr 29 2016
Valeant files overdue financial report, ending debt default, but its troubles aren't over Apr 29 2016
Valeant's 10-K: 'Chock Full of Troubling Insights' Apr 29 2016
Valeant files overdue financial report, ending debt default Apr 29 2016
Valeant files overdue financial report, ending debt default Apr 29 2016
Valeant tries corporate housecleaning Apr 29 2016
STOCKS SLIP: Here's what you need to know Apr 29 2016
Sequoia Reopens to New Investors Apr 29 2016
Valeant files overdue financials, averts debt default Apr 29 2016
Valeant CEO Michael Pearson Had Chance at $2.66 Billion Payday Apr 29 2016
Valeant 10-K First Read: No Big Surprises, Says Evercore Apr 29 2016
Goldman Sachs, Berkshire Hathaway and Valeant Apr 29 2016
Valeant announces nominees for an overhauled board, files overdue annual report Apr 29 2016
Stocks end rough week on a down note Apr 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK